Table 2 The relationship between lysophosphatidic acid receptor 2 (LPA2) expression and clinical/pathological factor
From: Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma
| LPA2 expression | Low (36) | High (48) | P |
|---|---|---|---|
| Age (years) | |||
| <50 | 20 (56%) | 16 (33%) | 0.042 |
| ≥50 | 16 (44%) | 32 (67%) | |
| Tumour size | |||
| T1 (≤2.0 cm) | 16 (44%) | 17 (35%) | NS |
| T2 (>2.0 cm to ≤5.0 cm) | 18 (50%) | 25 (52%) | |
| T3 (>5.0 cm) | 2 (6%) | 6 (13%) | |
| Nuclear grade | |||
| I | 5 (14%) | 5 (10%) | NS |
| II | 24 (67%) | 31 (65%) | |
| III | 7 (19%) | 12 (25%) | |
| Menopausal status | |||
| Premenopausal | 21 (58%) | 17 (35%) | 0.037 |
| Postmenopausal | 15 (42%) | 31 (65%) | |
| Oestrogen receptor status | |||
| Negative | 10 (55%) | 27 (56%) | NS |
| Positive | 8 (45%) | 21 (44%) | |
| Nodal metastasis | |||
| Negative | 12 (33%) | 21 (44%) | NS |
| Positive | 24 (67%) | 27 (56%) | |
| Distant metastasis | |||
| Negative | 27 (75%) | 41 (85%) | NS |
| Positive | 9 (25%) | 7 (15%) | |
